Glenmark Pharmaceuticals Limited has had a difficult run in the US in the fiscal first quarter though the firm expects things to steady hereon as new launches kick in, including the anticipated debut of Ryaltris (olopatadine hydrochloride/mometasone furoate nasal spray) “anytime now”.
At the earnings call for the fiscal first quarter ended 30 June 2022, Glenmark’s leadership echoed what some peers have been flagging up over the recent past – business in the US has been rather tough
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?